Legend Biotech price target raised to $65 from $53 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Legend Biotech to $65 from $53 and keeps an Overweight rating on the shares after the company reported Q4 Carvykti sales of $55M. The analyst raised the price target to reflect improved confidence in the drug’s earlier line opportunity.